Investors
A MESSAGE FROM OUR CEO
”Having extended patent protection until 2042 is pivotal for ensuring resomelagon’s value for us and future potential partners.”
-
May 27, 2025 RegulatoryBulletin from the annual general meeting 2025 in SynAct Pharma AB
-
May 27, 2025 RegulatorySynAct Pharma publishes Q1 2025 interim results
-
May 12, 2025 Non RegulatorySynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy